Synthetic Drug Candidates Available for Licensing
Explore the Psybrary™ Portfolios
57 of these novel molecules with unique receptor binding profiles and pharmacokinetic properties are available for out-licensing as potential drug candidates.
To the prospective partner, the molecules represent an opportunity for pipeline development and access to novel, protected compounds in a highly competitive and significant medical market.
For Enveric, the out-licensing made possible by the Psybrary™ Portfolios represents an opportunity to diversify risk while exploiting and retaining potential near term revenue streams across multiple drug candidates and markets.
Assets
# of Compounds
Receptor Binding
License Development
Bifunctional Psilocin Prodrug (BPP) Series
5 Novel Compounds
5HT2A, 5HT1A, 5HT1B, SERT, GABA
Novel Serotonin-Norepinephrine-Dopamine Inhibitor (SNDRI) Series
2 Novel Compounds
5HT1A, 5HT2A, SERT, DAT, NET
Melatonin Receptor Agonist (MRA) Series
16 Novel Compounds
MT1, SERT, 5HT1A, 5HT1C, 5HT2A, 5HT2B, 5HT2C
Novel MDMA Derivatives (EMD) Series
20 Novel Compounds
SERT, 5HT1A, 5HT2A, 5HT2C, alpha2A, D3, DAT, NET